New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:42 EDTMRKMerck announces new data from Phase 1b pembrolizumab study
Merck announced new data from the company’s large ongoing Phase 1b study evaluating pembrolizumab, Merck’s investigational anti-PD-1 antibody, as a single agent in 411 patients with advanced melanoma. Following treatment with pembrolizumab, the estimated overall survival rate at one year was 69% across all patients studied, including 74% in patients without prior ipilimumab therapy and 65% in patients who had progressive disease on or following ipilimumab. At 18 months, the estimated OS was 62%. The median OS has not been reached, with some patients receiving treatment with pembrolizumab as monotherapy for more than two years.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:35 EDTMRKCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
08:06 EDTMRKMerck, Sanofi unit announce pediatric hexavalent vaccine BLA
Subscribe for More Information
07:34 EDTMRKAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
07:19 EDTMRKIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTMRKAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 17, 2014
07:58 EDTMRKDeutsche Bank specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Gilbert provides of preview of The Improved Reduction of Outcomes: Vytorin Efficacy Internal Study (IMPROVE-IT) on an Analyst/Industry conference call to be held on October 17 at 10 am.
October 15, 2014
12:42 EDTMRKNY AG announces $31M Medicaid settlement with Organon
Subscribe for More Information
09:57 EDTMRKLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTMRKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
October 9, 2014
08:32 EDTMRKMerck HCV solutions becoming more credible, says Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use